The Neuphoria Therapeutics Inc. (NEUP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Neuphoria uses its Forms 10-K, 10-Q and 8-K, along with proxy materials and other statements, to report on its business, pipeline, governance and material events.
For NEUP, current reports on Form 8-K are especially informative. Recent 8-K filings have described outcomes from the AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder, the decision to discontinue further development of the SAD program, and the company’s plans for a full strategic review of its operations and portfolio. Other 8-Ks detail the adoption of a limited-duration stockholder rights plan, notices from The Nasdaq Stock Market LLC regarding listing rule compliance, and the holding of the company’s annual meeting of stockholders.
Neuphoria’s filings also include information on strategic and governance matters. A definitive proxy statement on Schedule 14A outlines proposals for director elections, auditor ratification, and advisory votes on executive compensation and its frequency. Additional 8-K disclosures describe changes in executive roles and the entry into a consulting agreement with the company’s former full-time CEO to serve as interim CEO during the strategic review and potential strategic transaction process.
Investors can use NEUP’s periodic reports, when available, to review financial statements, license revenue, research and development spending, and cash position, as well as risk factor discussions related to its CNS drug development programs and collaborations with partners such as Merck & Co., Inc. These documents also provide context on Neuphoria’s single operating segment focused on allosteric ion channel modulators.
On Stock Titan, NEUP filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the key points in lengthy filings, highlight important clinical and strategic disclosures, and make it easier to locate information on topics such as trial outcomes, rights plans, annual meeting results, and material agreements. This allows users to quickly understand what each filing means for Neuphoria’s business and capital markets profile without reading every page in full.
Neuphoria Therapeutics (NEUP) reported Q1 FY2026 results for the quarter ended September 30, 2025. Operating expenses were $5.65 million, driven mainly by R&D on BNC210. The company posted a net loss of $9.91 million and basic/diluted loss per share of $4.41. Other loss reflected a $4.37 million non‑cash decrease from fair value adjustments.
Cash and cash equivalents were $13.65 million, with total assets of $27.34 million and shareholders’ equity of $12.51 million. Subsequent to quarter end, the company raised approximately $15.1 million via its ATM, which management says supports operations beyond the second quarter of fiscal 2027. As of November 13, 2025, common shares outstanding were 5,377,329.
After quarter end, the AFFIRM‑1 Phase 3 trial in social anxiety disorder did not meet its primary endpoint, and the SAD program will be discontinued. The company plans to evaluate next steps for BNC210 in PTSD, initiated a strategic review, and adopted a limited-duration shareholder rights plan expiring October 27, 2026.
Neuphoria Therapeutics Inc. filed a preliminary proxy for its 2025 Annual Meeting set for December 12, 2025, to be held in a virtual-only format. Stockholders will vote on: (1) electing two Class I directors, (2) ratifying Wolf & Company P.C. as auditor for FY2026, (3) a non-binding advisory vote on executive compensation, and (4) a non-binding advisory vote on the frequency of say‑on‑pay (the board recommends three years).
The company faces a contested election. LYNX1 Master Fund LP is running two nominees and has mounted an opposing solicitation. The board recommends voting FOR its two Class I nominees on the WHITE proxy card and WITHHOLD on LYNX1’s nominees. The proxy explains the SEC’s universal proxy card framework and cautions that only the latest-dated proxy counts.
Background: LYNX1 filed a Schedule 13D reporting 875,328 shares and delivered a non‑binding proposal to acquire the company for $5.20 per share. The company issued a press release addressing the nomination and proposal and noted a review of strategic alternatives. Shares outstanding were 2,357,613 as of the October 15, 2025 record date.
Neuphoria Therapeutics Inc. will hold its virtual Annual Meeting on December 9, 2025 at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/NEUP2025. Stockholders of record at the close of business on October 15, 2025 may vote; 2,357,613 shares of Common Stock were outstanding on the record date.
Stockholders will vote on: (1) re‑election of Class I directors Peter Miles Davies and David Wilson to terms ending in 2028, (2) ratification of Wolf & Company P.C. as independent auditor for the fiscal year ending June 30, 2026, (3) a non‑binding advisory vote on executive compensation, (4) a non‑binding advisory vote on the frequency of say‑on‑pay, with the Board recommending every three years, and (5) authorization to adjourn the meeting to solicit additional proxies if needed.
The Board recommends voting in favor of all proposals (and “three years” for Proposal 4). Broker non‑votes are counted for quorum only and have no effect on non‑routine items. Internet/telephone voting closes at 11:59 p.m. Eastern on December 8, 2025.
Neuphoria Therapeutics Inc. (NEUP) adopted a limited‑duration stockholder rights plan and declared a dividend of one Right per outstanding common share to stockholders of record on October 27, 2025. The plan is designed to deter any person or group from acquiring 15% or more of the common stock without Board approval and follows rapid accumulations, including an investor that informed the Company it held over 20% as of October 23, 2025.
Each Right, after the Distribution Date, entitles the holder to buy 1/1,000th of a Series A Preferred Share at $85.00, subject to customary adjustments. The Rights expire on October 27, 2026, unless earlier redeemed or exchanged; the Board may redeem all Rights for $0.001 per Right before any person becomes an Acquiring Person. Holders above the threshold as of the announcement are grandfathered at current levels but may not increase ownership without triggering the Rights. The Company also announced it will evaluate strategic alternatives.
Neuphoria Therapeutics (NEUP) filed Amendment No. 6 to its prospectus supplement for its at-the-market program, permitting sales of up to $21,917,873 of common stock from time to time through H.C. Wainwright as sales agent.
Sales will be effected as an “at the market” offering under Rule 415(a)(4). Wainwright will receive a 3.0% commission on gross proceeds and will be deemed an underwriter; indemnification and contribution apply. The company states compliance with General Instruction I.B.6 of Form S‑3: public float was approximately $65,753,620 based on 3,287,681 non‑affiliate shares at $20.00 as of October 6, 2025, and it has sold $15,477,836 over the past 12 months under I.B.6.
The common stock trades on Nasdaq as NEUP; the last reported sale price was $6.24 on October 24, 2025.
Neuphoria Therapeutics Inc. (NEUP) disclosed an insider purchase on a Form 4. Reporting persons tied to Lynx1 Master Fund LP bought 639,110 shares of common stock on 10/21/2025 at a weighted average price of $5.137. The filing notes the trades occurred across prices from $4.96 to $5.20. After the transaction, the filing reports 875,328 shares beneficially owned on an indirect basis. The reporting person’s relationship box indicates Director.
The filing explains that the securities are held by Lynx1 Master Fund LP, with Lynx1 Capital Management LP as investment manager and Weston Nichols as the sole member of the manager’s general partner, and includes customary beneficial ownership disclaimers.
Neuphoria Therapeutics Inc. (NEUP) received an initial ownership report on Form 3. The filing lists “Director” as the relationship to the issuer and indicates the form was filed by more than one reporting person. The event date is 10/21/2025.
The report shows 236,218 shares of common stock beneficially owned on an indirect basis, held by Lynx1 Master Fund LP. The filing explains that Lynx1 Capital Management LP serves as investment manager to the fund and Weston Nichols is the sole member of the fund manager’s general partner. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
NeuroBo Pharmaceuticals (NEUP) amended its prospectus supplement to update its at-the-market program, allowing sales of up to $15,478,160 of common stock from time to time through H.C. Wainwright & Co. as sales agent under a previously executed Sales Agreement. Sales may be made in transactions deemed an at-the-market offering under Rule 415(a)(4).
The update reflects eligibility under General Instruction I.B.6 of Form S-3, which limits primary sales to no more than one-third of public float in any 12-month period while public float is below $75 million. Public float was $46,434,480, based on 2,321,724 non-affiliate shares at $20.00 as of October 6, 2025. In the past 12 months, the company sold $5,352,879 under I.B.6. Wainwright earns a 3.0% commission on gross proceeds.
Neuphoria Therapeutics (NEUP) reported topline results from its AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder, stating the study did not meet its primary endpoint on the SUDS score during the public speaking performance phase. Analyses of secondary endpoints also did not show statistically significant differences versus placebo.
The company noted BNC210’s safety and tolerability remained favorable and consistent with prior studies. Neuphoria highlighted its partnership with Merck, under which Merck is running a Phase 2 trial of MK-1167 in Alzheimer’s disease and is responsible for all costs; the collaboration includes eligibility for up to $450 million in additional milestone payments plus royalties on net sales of any licensed medicines.
As of June 30, 2025, cash and cash equivalents were $14.2 million. The company expects its current cash position to fund operations through the second fiscal quarter of 2027.
Neuphoria Therapeutics (NEUP) is advancing BNC210, an oral selective negative allosteric modulator of the α7 receptor, across acute social anxiety disorder (SAD) and chronic PTSD programs while maintaining a broader CNS pipeline and partnerships. The Phase 2b ATTUNE PTSD trial met its primary endpoint (CAPS-5 change; p=0.048) with additional statistically significant benefits on depressive symptoms and sleep. PREVAIL narrowly missed its primary public-speaking SUDS endpoint but showed encouraging phase-specific and secondary trends.
The company initiated screening for Phase 3 AFFIRM-1 in SAD targeting ≈332 adults with topline results expected early Q4 2025, and plans a Phase 2b/3 PTSD study contingent on capital. Neuphoria holds multiple patent families with potential protection through 2040, collaborative arrangements including Merck and Carina, and faces typical biotech risks including need for additional capital, regulatory approvals, manufacturing scale-up, and safety monitoring for liver function.